ZENTALIS PHARMACEUTICALS INC. - COMMON STOCK

Zentalis Pharmaceuticals Announces Key Management Appointments

12 12月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 12月 2024 16:35:10 条件 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Executive Leadership Changes Supporting Planned Registrational Clinical Studies of Azenosertib

13 11月 2024 08:00:00 条件 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 11月 2024 19:04:44 条件 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies

16 9月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024

09 9月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 9月 2024 16:40:50 条件 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Progress

09 8月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 8月 2024 18:00:00 条件 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 7月 2024 18:00:47 条件 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program

18 6月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 6月 2024 18:00:55 条件 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

30 5月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors

29 5月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting

23 5月 2024 17:01:39 条件 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation Summit

14 5月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress

07 5月 2024 07:00:01 条件 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 5月 2024 17:30:00 条件 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024

02 4月 2024 16:05:00 条件 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 4月 2024 17:30:00 条件 Nasdaq GlobeNewswire